Last reviewed · How we verify

Zai Lab (Shanghai) Co., Ltd. — Portfolio Competitive Intelligence Brief

Zai Lab (Shanghai) Co., Ltd. pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ZL-1310 ZL-1310 phase 3 FGFR inhibitor FGFR (Fibroblast Growth Factor Receptor) Oncology
Investigator's Choice of Therapy Investigator's Choice of Therapy phase 3
ZL-1109 (VRDN-003) ZL-1109 (VRDN-003) phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 shared drug classes
  2. GlaxoSmithKline · 2 shared drug classes
  3. Eli Lilly and Company · 2 shared drug classes
  4. ATGC Co., Ltd. · 1 shared drug class
  5. Akeso · 1 shared drug class
  6. Allist Pharmaceuticals, Inc. · 1 shared drug class
  7. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  8. Amgen · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zai Lab (Shanghai) Co., Ltd.:

Cite this brief

Drug Landscape (2026). Zai Lab (Shanghai) Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zai-lab-shanghai-co-ltd. Accessed 2026-05-16.

Related